Range Low Price High Price Comment
30 days $1.15 $1.72 Wednesday, 1st May 2024 APTO stock ended at $1.21. This is 0.83% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 3.36% from a day low at $1.19 to a day high of $1.23.
90 days $1.15 $2.20
52 weeks $0.360 $6.60

Historical Aptose Biosciences prices

Date Open High Low Close Volume
Feb 02, 2016 $2.92 $2.92 $2.92 $2.92 13 400
Feb 01, 2016 $2.89 $2.89 $2.89 $2.89 26 400
Jan 29, 2016 $2.94 $2.94 $2.94 $2.94 13 300
Jan 28, 2016 $2.97 $2.97 $2.97 $2.97 20 600
Jan 27, 2016 $2.92 $2.92 $2.92 $2.92 32 500
Jan 26, 2016 $2.90 $2.90 $2.90 $2.90 28 900
Jan 25, 2016 $2.56 $2.56 $2.56 $2.56 17 300
Jan 22, 2016 $2.49 $2.49 $2.49 $2.49 20 200
Jan 21, 2016 $2.27 $2.27 $2.27 $2.27 9 200
Jan 20, 2016 $2.14 $2.14 $2.14 $2.14 5 000
Jan 19, 2016 $2.07 $2.07 $2.07 $2.07 10 000
Jan 15, 2016 $2.12 $2.12 $2.12 $2.12 6 400
Jan 14, 2016 $2.10 $2.10 $2.10 $2.10 3 600
Jan 13, 2016 $2.11 $2.11 $2.11 $2.11 8 600
Jan 12, 2016 $2.16 $2.16 $2.16 $2.16 14 000
Jan 11, 2016 $2.28 $2.28 $2.28 $2.28 8 500
Jan 08, 2016 $2.32 $2.32 $2.32 $2.32 11 400
Jan 07, 2016 $2.30 $2.30 $2.30 $2.30 17 100
Jan 06, 2016 $2.31 $2.31 $2.31 $2.31 6 200
Jan 05, 2016 $2.48 $2.48 $2.48 $2.48 16 300
Click to get the best stock tips daily for free!

About Aptose Biosciences

Aptose Biosciences Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Ph... APTO Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT